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Abstract
Platelet-activating factor (PAF) is a potent phospholipid mediator that exerts various 
pathophysiological effects by interacting with a G protein-coupled receptor. PAF has been reported 
to increase the permeability of the blood-brain barrier (BBB) via incompletely characterized 
mechanisms. We investigated the effect of PAF on rat brain microvascular endothelial cells 
(RBMVEC), a critical component of the BBB. PAF produced a dose-dependent increase in 
cytosolic Ca2+ concentration; the effect was prevented by the PAF receptor antagonist, WEB2086. 
The effect of PAF on cytosolic Ca2+ was abolished in Ca2+-free saline or in the presence of L-type 
voltage-gated Ca2+ channel inhibitor, nifedipine, indicating that Ca2+ influx is critical for PAF-
induced increase in cytosolic Ca2+. PAF produced RBMVEC depolarization; the effect was 
inhibited by WEB2086. In cells loaded with DAF-FM, a nitric oxide (NO)-sensitive fluorescent 
dye, PAF increased the NO level; the effect was prevented by WEB2086, nifedipine or by L-
NAME, an inhibitor of NO synthase. Immunocytochemistry studies indicate that PAF reduced the 
immunostaining of ZO-1, a tight junction-associated protein, increased F-actin fibers, and 
produced intercellular gaps. PAF produced a decrease in RBMVEC monolayer electrical 
resistance assessed with Electric Cell-Substrate Impedance Sensing (ECIS), indicative of a 
disruption of endothelial barrier function. In vivo studies indicate that PAF increased the BBB 
permeability, assessed with sodium fluorescein and Evans Blue methods, via PAF receptor-
dependent mechanisms, consequent to Ca2+ influx and increased NO levels. Our studies reveal 
that PAF alters the BBB permeability by multiple mechanisms, which may be relevant for central 
nervous system (CNS) inflammatory disorders.
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Introduction
Platelet-activating factor (PAF) is a bioactive phospholipid messenger, originally reported to 
produce platelet aggregation after being released from IgE-sensitized basophils (Benveniste 
et al., 1972). In addition to platelet activation, PAF has been ascribed to other physiological 
and pathophysiological functions (Prescott et al., 2000, Liu et al., 2016). PAF is a potent 
inflammatory factor, involved in pathogenesis of several diseases such as anaphylaxis, 
asthma, rheumatoid arthritis, atherosclerosis, glomerulosclerosis, and diabetes (Hilliquin et 
al., 1995, Prescott et al., 2000, Tsoupras et al., 2009, Liu et al., 2016). PAF also induces 
smooth muscle contraction, and increases vascular permeability (Kornecki and Ehrlich, 
1988, Lacerda-Queiroz et al., 2012, Vadas et al., 2013, Jeewandara et al., 2015).
PAF synthesis occurs via two pathways
de novo, and by the cytosolic phospholipase A2-dependent remodeling pathway, with the 
latter being predominant (Liu et al., 2016). Similarly to the eicosanoids, PAF is not stored 
preformed, but rapidly synthesized intracellularly in response to cell-specific stimuli 
(Prescott et al., 2000). Synthesis and release of PAF occur in a variety of cells, 
predominantly in endothelial cells and leukocytes (Aliberti et al., 1999, Mariano et al., 
2003). The synthesis, distribution and degradation of PAF are tightly controlled, contributing 
to brief and selective responses (Prescott et al., 2000).
PAF exerts its effects by interaction with a G protein-coupled receptor, namely PAF receptor 
(Alexander et al., 2015). PAF receptor, the first cloned receptor for lipids, is expressed in a 
variety of cell types (Honda et al., 1991, Bito et al., 1994, Ihida et al., 1999), including brain 
microvascular cells (Predescu et al., 1996). Activation of the PAF receptor promotes inositol 
trisphosphate (IP3) formation via phospholipase C (PLC) stimulation; it also stimulates 
protein kinases, such as protein kinase C and tyrosine kinase (Barzaghi et al., 1989, Shukla, 
1992). In addition, PAF was shown to produce Ca2+ influx in cell lines such as NG108-15, 
mouse neuroblastoma-rat glioma cells, and PC12, rat pheochromocytoma cells (Kornecki 
and Ehrlich, 1988).
In the central nervous system (CNS), PAF was involved in the inflammatory response, 
pathogenesis of meningitis, ischemia-reperfusion injury, stroke, multiple sclerosis, 
Alzheimer's and Parkinson's diseases, or HIV-associated neurocognitive disorders 
(Feuerstein, 1996, Maclennan et al., 1996, Liu et al., 2016, Reiner et al., 2016). PAF has 
been reported to produce a transient increase in blood-brain barrier (BBB) permeability 
(Fang et al., 2011, Fang et al., 2014), however the effects of PAF on endothelial cells of the 
BBB remain incompletely characterized. The current study investigated the effects elicited 
by PAF on rat brain microvascular endothelial cells, an experimental model of BBB, on 
cytosolic Ca2+ concentration, membrane potential, nitric oxide (NO) level and electrical 
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resistance. In addition, in vivo studies examined the contribution of the pathways identified 
for PAF in vitro on the rat BBB permeability.
Experimental Procedures
Ethical approval
Animal protocols were approved by the Institutional Animal Care and Use Committee from 
each institution.
Chemicals and reagents
PAF (C-16 PAF) and WEB2086 were from Tocris Biosciences (Bristol, UK). Fura-2AM, 
DAF-FM, DiBAC4(3), and ActinRed555 were from Molecular Probes (ThermoFisher 
Scientific, Waltham, MA). Other reagents were from Sigma-Aldrich (St. Louis, MO) unless 
otherwise mentioned.
Cell Culture
Rat brain microvascular endothelial cells (RBMVEC), purchased from Cell Applications, 
Inc (San Diego, CA) were cultured as previously described (Altmann et al., 2015, Brailoiu et 
al., 2017). Cells were grown in endothelial basal medium enriched with endothelial growth 
supplement, in T75 flasks coated with attachment factor (Cell Applications, Inc). For 
immunocytochemistry studies, cells were plated on 12 mm diameter glass coverslips. For 
live imaging studies, cells were grown on 25 mm diameter glass coverslips coated with 
human fibronectin (Discovery Labware, Bedford, MA). For impedance measurements, cells 
were grown on 8W10E+ arrays (Applied BioPhysics, Inc., Troy, NY) coated with 
fibronectin.
Cytosolic Ca2+ measurement
Cytosolic Ca2+ concentration, [Ca2+]i, was assessed in RBMVEC loaded with Fura-2 AM 
(Molecular Probes, ThermoFisher Scientific, Waltham, MA), as previously described 
(Altmann et al., 2015, Brailoiu et al., 2016, Brailoiu et al., 2017). Cells on coverslips were 
incubated with Fura-2 AM (5 μM, 1 hour, room temperature) in Hanks' Balanced Salt 
Solution (HBSS). Coverslips, after washing with dye-free HBSS, were mounted on the stage 
of a Nikon Eclipse TiE microscope (Nikon Inc., Melville, NY), in an open bath chamber. 
Fura-2 AM fluorescence (emission 510 nm), following alternate excitation at 340 and 380 
nm, was recorded using a Photometrics CoolSnap HQ2 CCD camera (Photometrics, Tucson, 
AZ) and NIS-Elements AR software (Nikon). The ratio of the fluorescence signals (340/380 
nm) was converted to Ca2+ concentrations (Grynkiewicz et al., 1985).
Measurement of membrane potential
Changes in RBMVEC membrane potential were assessed using a voltage-sensitive dye, bis-
(1,3-dibutylbarbituric acid)-trimethine-oxonol, DiBAC4(3) (Molecular Probes), as reported 
(Brauner et al., 1984, Altmann et al., 2015). RBMVEC were incubated in DiBAC4(3) (0.5 
μM in HBSS, 30 min) and the fluorescence (excitation/emission 480 nm/540 nm) monitored. 
Membrane depolarization produces an increase in fluorescence intensity consequent to 
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accumulation of the dye into the cytosol, (Brauner et al., 1984). Calibration of DiBAC4(3) 
fluorescence was performed as previously reported (Altmann et al., 2015).
NO measurement
Intracellular NO was measured in RBMVEC loaded with DAF-FM [(4-amino-5-
methylamino-2′,7′-difluoro-fluorescein) diacetate] (Molecular Probes) as described 
(Kojima et al., 1998, Altmann et al., 2015). RBMVEC were incubated in DAF-FM (0.5 μM 
in HBSS, 45 min, room temperature) (Leikert et al., 2001) and the DAF-FM fluorescence 
(excitation/emission 480 nm/ 540 nm was monitored.
Immunocytochemistry
Immunocytochemistry studies were performed as described earlier (Brailoiu et al, 2011, 
Brailoiu et al, 2017). RBMVEC grown on 12 mm diameter glass coverslips, were treated for 
10 min with PAF (1 μM), WEB2086 (5 μM), L-NAME (100 μM), nifedipine (1 μM). in 
other experiments, cells were treated with WEB2086, L-NAME or nifedipine for 15 min, 
followed by PAF for 10 min; untreated cells served as control. After rinsing with phosphate 
buffer saline (PBS), cells were fixed in 4% paraformaldehyde. Cell fixation was followed by 
additional rinsing with PBS and PBS with 0.5% Triton X for 5 min, and incubation with 
normal goat serum. Cells were then incubated with primary antibody ZO-1 (rabbit IgG, 
Molecular Probes) overnight at 4°C, followed by incubation with secondary antibody (goat 
anti-rabbit, conjugated to Alexa 488, 2 hours, room temperature). Cells were washed in PBS 
and incubated with ActinRed 555 (30 min, room temperature). After washing in PBS, cells 
were mounted with DAPI Fluoromount G (SouthernBiotech, Birmingham, AL), sealed, and 
examined under a Leica DMI6000B fluorescence microscope.
Impedance Measurements
Impedance measurements were carried out via electric cell-substrate impedance sensing 
(ECIS) method, using a Zθ controller, an 16W array holder station and 8W10E+ arrays, 
similarly with previous reports (Stolwijk et al, 2015, Stolwijk et al, 2016). RBMVEC were 
cultured at a density of 100,000 cells/cm2 on 8W10E+ arrays treated with L-cysteine (10 
mM, 200 μl/well, 20 min, room temperature) and coated with fibronectin (50μg/ml, 200 μl/
well, 30 min, 37°C). Cells were grown on arrays for 48 h in an incubator (37°C, 5% CO2, 
humidified atmosphere) before drug treatment. To assess the change in paracellular currents 
in response to agonists (PAF and histamine), the resistance part of impedance, was 
normalized to the value before the addition of the agonist and plotted as function of time.
MTT assay
We assessed the cell viability using a colorimetric assay with methylthiazolyldiphenyl-
tetrazolium bromide (MTT). This assay is based on the conversion of the water-soluble 
tetrazolium salt (yellowish) by mitochondrial dehydrogenase of living cells to water-
insoluble formazan (dark-blue). RBMVEC were cultured in 96-well plates at a density of 
10,000 cells/well. After 48 hours in culture, cells were treated with PAF (0.1- 5 μM) for one 
hour. Cells were treated with MTT (10 μl/well) and incubated at 37°C for 3 hours. The 
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medium containing MTT was removed and DMSO (50 μl/well) added. After gently mixing 
for 5 min, the absorbance at 570 nm was read using a Synergy plate reader.
Permeability assay with sodium fluorescein
BBB permeability was assessed by measuring the sodium fluorescein content in the rat 
brain, similarly with previous reports (Lenzser et al., 2007). The drugs tested or saline 
(control) were administered i.v. in the tail vein 30 min after systemic injection of sodium 
fluorescein (2%, 4 mL/kg). One hour after drug administration, the rats were anesthetized 
and transcardially perfused with ice-cold PBS. The brain was removed, rinsed, weighted and 
homogenized in PBS. The homogenate was treated with trichloroacetic acid (80%), then 
centrifuged (20 mins, 10,000g). The supernatant was diluted with 5 M NaOH, and its 
fluorescence was determined (excitation/emission- 440 nm/525 nm) using a microplate 
reader. The concentration of sodium fluorescein in the brain was quantified and expressed 
per gram of tissue.
Evans Blue extravasation method
BBB disruption was assessed quantitatively by measuring Evans Blue extravasation as 
previously reported (Uyama et al., 1988, Radu and Chernoff, 2013). Evans blue 2% in PBS 
(4 mg/Kg) was injected i.v. via tail vein, 30 min before the administration of drugs tested. 
One hour later, rats were anesthetized with ketamine (100 mg/kg) and perfused 
transcardially with PBS. The brain was dissected, weighed and homogenized in PBS. The 
homogenate was treated with trichloroacetic acid (80%,), incubated at 4 °C, 1 h and 
centrifuged (20 min, 10,000 g). The supernatant's absorbance at 610 nm was determined 
using a plate reader. Brain Evans Blue concentration was quantified from a linear standard 
curve plotted from known amounts of Evans Blue dye.
Statistical analysis
Data were expressed as mean ± standard error of mean. One-way ANOVA followed by 
Bonferonni and Tukey tests was used to evaluate significant differences between groups; P < 
0.05 was considered statistically significant.
Results
PAF increases cytosolic Ca2+ concentration, [Ca2+]i , in RBMVEC
The cytosolic Ca2+ concentration, [Ca2+]i, before and after treatment with PAF was assessed 
in Fura 2-AM-loaded RBMVEC cells. PAF (1 μM) increased the RBMVEC fluorescence 
ratio F340/F380 (Fig. 1A). The increase in fluorescence was converted to Ca2+ concentration 
(Grynkiewicz et al., 1985). PAF produced a fast and transient increase in [Ca2+]i, that was 
inhibited by the PAF receptor antagonist, WEB2086 (5 μM). Cells were pretreated with 
WEB2086 for 15 min before PAF treatment. Examples of averaged Ca2+ responses induced 
by PAF, and by PAF in the presence of WEB2086 are shown in Fig 1B. The comparison of 
the amplitude of Ca2+ responses produced by different concentrations of PAF (0.1-5 μM) is 
shown in Fig. 1C. PAF (0.1 μM, 0.5 μM, 1 μM and 5 μM) produced an increase in [Ca2+]i by 
73 ± 1.9 nM, 146 ± 2.7 nM, 579 ± 4.16 nM, and 638 ± 5.09 nM, respectively (n= 35-65 
cells) (Fig. 1C).
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PAF promotes Ca2+ influx in RBMVEC
In Ca2+-free saline, or in the presence nifedipine (1μM), a L-type Ca2+ channels blocker the 
Ca2+ response to PAF (1μM) was absent. Cells were pretreated with nifedipine 15 min 
before PAF treatment. To verify the functionality of internal Ca2+ stores in RBMVEC, we 
tested the Ca2+ response produced by ATP, an agonist known to generate inositol 1,4,5-
trisphosphate (IP3) and consequent Ca2+ release from endoplasmic reticulum Ca2+ stores. In 
Ca2+-free saline, ATP (50 μM) induced a fast and transient increase in [Ca2+]i. Typical 
examples of Ca2+ responses are shown in Fig. 1D and the comparison of the amplitude in 
[Ca2+]i increase in each condition, is shown in Fig. 1E. In Ca2+-free saline, PAF (1 μM) 
produced a minimal increase in [Ca2+]i by only 18 ± 2.23 nM (n = 45 cells), as compared to 
an increase of [Ca2+]i by 579 ± 4.16 in Ca2+-containing saline. ATP (50 μM) increased Ca2+ 
by 248 ± 4.36 nM (n = 53 cells) in Ca2+-free saline. Pre-treatment with nifedipine (1μM, 15 
min), similarly to Ca2+-free saline condition, inhibited the response to PAF; Δ [Ca2+]i = 11 
± 1.97 nM (n= 43 cells), indicating that the PAF-induced increase in [Ca2+]i was produced 
by Ca2+ influx.
PAF depolarized RBMVEC
The effect of PAF on membrane potential was monitored in RBMVEC loaded with 
DiBAC4(3). PAF (1μM) produced a depolarization with an average amplitude o f 8.27 ± 0.38 
mV (n = 35 cells); in the presence of WEB2086, the effect of PAF was markedly 
diminished; ΔV = 1.35 ± 0.24 mV. Pretreatment with nifedipine (1μM, 15 min), prevented 
the PAF-induced depolarization (ΔV = 0.81 ± 0.21 mV), while L-NAME did not affect the 
response to PAF (ΔV = 8.03 ± 0.41 mV). Averaged changes in membrane potential produced 
by PAF in each condition are shown in Fig. 2A, and the comparison of the amplitude of 
depolarization produced in each condition is shown in Fig. 2B.
PAF increases NO in RBMVEC
In cells loaded with DAF-FM, a NO-sensitive dye (Kojima et al, 1998), PAF (1 μM) 
increased DAF-AM fluorescence ratio (Fig. 3). The response was abolished by WEB2086, a 
PAF receptor antagonist, by L-NAME (100 μM), NO synthase inhibitor, or by nifedipine, a 
L-type Ca2+ channel antagonist (Fig. 3A). PAF (1 μM) increased the fluorescence by about 
30% (Δ DAF-FM = 0.32 ± 0.027). WEB2086, L-NAME and nifedipine reduced the response 
to PAF to levels similar to control; ΔDAF-FM = 0.02 ± 0.011 in cells pretreated with 
WEB2086, 0.016 ± 0.008 in cells pretreated with L-NAME, and 0.057 ± 0.011 in RBMVEC 
treated with nifedipine (Fig. 3B).
PAF alters RBMVEC cytoskeleton and tight junctions
We examined the distribution of ZO-1, a regulatory protein used as a marker for tight 
junctions complex (Abbott et al., 2010, Molino et al., 2014) before and after treatment of 
RBMVEC with PAF (1 μM). Treatment with PAF reduced the peripheral ZO-1 staining 
indicative of disruption of tight junctions, and increased the formation of F-actin fibers, 
suggesting cytoskeletal changes (Fig. 4A). Moreover, PAF promoted the intercellular gap 
formation (Fig. 4A). Treatment of RBMVEC with WEB2086, L-NAME and nifedipine 
while did not affect the ZO-1 and actin staining, but prevented the changes elicited by PAF.
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PAF disrupts endothelial barrier function
ECIS experiments indicate that treatment of RBMVEC monolayers with PAF (1 μM) 
produced a transitory decrease in the resistance part of impedance (Fig. 4B), indicative of 
barrier function disruption. Blockade of PAF receptor with WEB2086 (5 μM) prevented the 
response to PAF. The barrier-disruptive effect of histamine (10 μM) was used as a positive 
control (Stolwijk et al., 2015, Stolwijk et al., 2016).
PAF did not affect RBMVEC viability
Since earlier studies (Fang et al., 2011, Predescu et al., 2013) indicate that PAF at 
concentration higher than 10-7 M had cytotoxic effects, we examined the effect of PAF on 
RBMVEC viability, in our experimental conditions. Treatment with PAF (0.1 μM, 0.5 μM, 1 
μM and 5 μM) for one hour, did not significantly affect the viability of RBMVEC, assessed 
with MTT assay (Fig. 4C)
PAF increases BBB permeability
In vivo studies examined the effect of systemic administration of PAF on the BBB 
permeability by determining the concentration of sodium fluorescein and Evans Blue in the 
rat brain. In control rats, the brain concentration of sodium fluorescein was 386 ± 47 ng/mg 
(n = 6). Treatment with PAF (0.01 mg/kg) increased the brain concentration of sodium 
fluorescein to 703 ± 84 ng/mg (n = 6). On the other hand, administration of WEB2086 (0.5 
mg/kg), L-NAME (20 mg/kg), or nifedipine (0.3 mg/kg) 10 min before PAF reduced the 
sodium fluorescein concentration in the brain to 426 ± 39 ng/mg, 402 ± 53 ng/mg and 447 
± 61 ng/mg (n = 6), respectively (Fig. 5A). In experiments where BBB permeability was 
assessed using Evans Blue, in control rats, the brain concentration of Evans Blue as 471 ± 54 
ng/mg (n = 6). Treatment with PAF (0.01 mg/kg) increased the brain concentration of Evans 
Blue to 1138 ± 74 ng/mg (n = 6). On the other hand, administration of WEB2086 (0.5 mg/
kg), L-NAME (20 mg/kg), or nifedipine (0.3 mg/kg) 10 min before PAF reduced the Evans 
Blue concentration in the brain to 557 ± 61 ng/mg, 582 ± 64 ng/mg and 541 ± 67 ng/mg (n = 
6), respectively (Fig. 5B).
Discussion
Platelet-activating factor (PAF) is a phospholipid mediator involved in various 
cardiovascular and CNS disorders (Prescott et al., 2000). While low basal PAF level was 
detected in the brain (Kumar et al., 1988), increased brain PAF levels occurred after hypoxia 
and reoxygenation injury (Deng et al., 2009), in response to convulsant stimuli (Kumar et 
al., 1988) or in pathological conditions like multiple sclerosis (Callea et al., 1999) or HIV-1 
infection (Gelbard et al., 1994). In addition to the synthesis in inflammatory cells, PAF can 
also be produced by endothelial cells (Liu et al., 2016). In a porcine model, cultured brain 
microvascular endothelial cells were reported to produce smaller amounts of PAF than aortic 
endothelial cells (Satoh et al., 1995). As previous reports indicate that PAF produced an 
increase in blood-brain barrier (BBB) permeability (Fang et al., 2011, Fang et al., 2014), we 
examined the effect of PAF on rat brain endothelial cells (RBMVEC), an essential 
component of the BBB.
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We found that in RBMVEC, PAF (0.1 - 5 μM) increased cytosolic Ca2+ concentration, 
[Ca2+]i in a dose-dependent manner. Lower concentrations of PAF tested here (0.1 μM, 0.5 
μM) mimic those found physiologically, while higher concentrations (>1 μM) were similar 
to those found in inflammatory conditions (Reiner et al., 2016). The effect of PAF was 
inhibited by the PAF receptor antagonist, WEB2086 (Ukena et al., 1988), furthering the 
implication of PAF receptor activation as the impetus for the cytosolic Ca2+ increase 
observed. Similarly, PAF increased [Ca2+]i in several other cell models like human 
monocytic leukemic U-937 cells (Barzaghi et al., 1989), hippocampal neurons (Bito et al., 
1992), N1E-115 neuroblastoma cells (Diserbo et al., 1995), human and canine aortic 
endothelial cells (Bkaily et al., 1993), bovine cerebral microvascular endothelial cells (Lin 
and Rui, 1994), oviductal cells (Tiemann et al., 1996, Tiemann et al., 1999) and rat brain 
microvessel endothelial cells (Deng et al., 2009). Earlier studies indicate that PAF produced 
phosphoinositide hydrolysis, synthesis of inositol phosphates and release of Ca2+ from 
endoplasmic reticulum stores, suggestive of Gq-protein signaling (Shukla, 1992, Kamata et 
al., 1993b). PAF receptor has been reported to signal also via Go and Gi proteins (Alexander 
et al., 2015).
In RBMVEC, Ca2+ influx and not Ca2+ release from internal stores was responsible for the 
increase in [Ca2+]i produced by PAF. Significant differences were reported in different 
cellular models between Ca2+ sources mobilized by PAF. While release of Ca2+ from 
internal stores was responsible for part of the Ca2+ increase, Ca2+ influx was considered the 
predominant mechanism elicited by PAF in platelets (Hallam et al., 1984), and U-397 cells 
(Barzaghi et al., 1989). In human airway epithelial cells (Stoll et al., 1994), or N1E-115 
neuroblastoma cells (Diserbo et al., 1995) PAF produced both a Ca2+ release from internal 
stores and Ca2+ influx. On the other hand, in NG108 cells (Kornecki and Ehrlich, 1988), 
human platelets (Avdonin et al., 1991), bovine oviductal cells (Tiemann et al., 1996, 
Tiemann et al., 1999) similarly to RBMVEC, PAF produced Ca2+ influx. However, in 
oviductal cells, PAF-induced Ca2+ influx was not affected by verapamil (Tiemann et al., 
1996), but blocked by flufenamic acid or TMB-8 (Tiemann et al., 1999), indicating the 
involvement of non-selective cationic channels. In bovine cerebral microvascular endothelial 
cells, PAF increased [Ca2+]i via phospholipase C-dependent mechanism, while blockade of 
Ca2+ influx with diltiazem or verapamil did not affect the response (Lin and Rui, 1994). On 
the other hand, in RBMVEC, PAF produced Ca2+ influx was sensitive to nifedipine, 
indicating the participation of L-type voltage-gated Ca2+ channels, and supporting different 
Ca2+ influx mechanisms between different cell types and/or species differences.
An increase in [Ca2+]i may lead to an increase in NO production consequent to the Ca2+-
dependent activation of endothelial NO synthase (eNOS) (Fleming et al., 1997). In 
RBMVEC, PAF produced an increase in NO levels; the effect was sensitive to the PAF 
receptor antagonist and NO synthase inhibitor. In addition, the increase in NO produced by 
PAF was abolished by a L-type Ca2+ channel blocker, indicating that the increase in [Ca2+]i 
by Ca2+ influx was a determinant of NO production. PAF has been reported to increase NO 
production via eNOS phosphorylation in other endothelial cells such as mouse pulmonary 
artery and lung microvascular endothelial cells (Predescu et al., 2013) and bovine coronary 
postcapillary venular endothelial cells (Sanchez et al., 2008) and produced subsequent 
increase in permeability. While these earlier studies examined the structural and functional 
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relationship of PAF receptor and eNOS at the plasma membrane microdomains, we 
examined the PAF-induced NO production in the context of the effect of PAF on [Ca2+]i 
concentration, membrane potential and their significance on endothelial permeability in vitro 
and in vivo.
We also identified that PAF depolarized RBMVEC loaded with a slow response voltage-
sensitive fluorescent dye, DiBAC4(3); the response was significantly diminished by 
antagonism of PAF receptor or by inhibition of Ca2+ influx. Similarly, earlier studies 
reported that PAF depolarized human or rabbit neutrophils (Naccache et al., 1986, Lerner et 
al., 1988) human platelets (Avdonin et al., 1991), bovine oviductal cells (Tiemann et al., 
1999) or rat stomach fundus (Kamata et al., 1993a). Depolarization of vascular endothelial 
cells was associated with NO production and increased cellular stiffness via reorganization 
of cortical actin cytoskeleton (Callies et al., 2011).
Brain microvascular endothelial cells are characterized by low paracellular permeability due 
to the presence of tight junctions between adjacent cells (Abbott et al., 2010). Tight 
junctional complex comprises of occludin, claudins and regulatory zonula occludens 
(Coeffier et al.) proteins (Aijaz et al., 2006). ZO-1, an intracellular regulatory protein, links 
the tight junctions molecules claudin and occludin to intracellular actin and the cytoskeleton 
and is widely used as a marker for tight junctions (Hawkins and Davis, 2005, Abbott et al., 
2010). Our results indicate that, in RBMVEC, PAF reduced ZO-1 staining. Similarly, PAF 
reduced ZO-1 expression in human umbilical vein endothelial cells (HUVEC) (Jeewandara 
et al., 2015). A decrease in ZO-1 expression or immunoreactivity has been associated with 
an increase in BBB permeability (Abbruscato et al., 2002, Hawkins and Davis, 2005, 
Reinhold and Rittner, 2017). PAF also produced an increase in F-actin staining and induced 
intercellular gaps. Similar changes were produced in microvascular endothelial cells by 
other agonists such as bradykinin (Liu et al., 2008), thrombin (Stolwijk et al., 2016, Brailoiu 
et al., 2017) and glutamate (Andras et al., 2007) or by hypoxia (Brown and Davis, 2005). In 
human dermal microvascular endothelial cells (HDMEC), actin fibers were found to 
redistribute to the cytosol 2-5 min after thrombin stimulation and toward the cell membrane 
after 30 min (Stolwijk et al., 2016). PAF increased actin cytoskeleton in rabbit neutrophils 
(Naccache et al., 1986) and increased contractility of rat stomach fundus (Kamata et al., 
1993a).
In endothelial cells, an increase in [Ca2+]i modulates junctional and cytoskeletal proteins, 
promotes phosphorylation of myosin light chain kinase, actin-myosin interaction and 
increases paracellular permeability (De Bock et al., 2013). Our ECIS experiments indicate 
that PAF decreased the electrical resistance, indicative of an increase in paracellular current 
flow. Similarly, PAF decreased electrical resistance in mouse pulmonary artery and lung 
microvascular endothelial cells (Predescu et al., 2013). A previous report indicates that the 
decrease in the trans-endothelial resistance (TEER) of HUVECs produced by PAF from the 
serum of patients with dengue fever played a critical role in the increased vascular 
permeability (Jeewandara et al., 2015). PAF was involved in the increase vascular 
permeability in experimental cerebral malaria (Lacerda-Queiroz et al, 2012) and anaphylaxis 
(Vadas et al, 2013). Other GPCR agonists, such as thrombin or histamine, were shown to 
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produce endothelial barrier dysfunction subsequent to morphological changes, 
rearrangement of actin cytoskeleton and junctional proteins (Stolwijk et al, 2016).
To further determine the significance of our in vitro studies, we investigated the in vivo 
effects of PAF on BBB permeability in rat, assessed with sodium fluorescein and Evans 
Blue. Earlier in vivo studies reported the PAF (1 μM, 1 h) induced transient and reversible 
BBB opening (Fang et al, 2014), while longer exposure to PAF (1 μM, 24h) increased 
permeability of RBMEC by upregulating intercellular adhesion molecule-1 (ICAM-1) and 
had cytotoxic effect (Fang et al, 2011). Our in vivo studies indicate that PAF increased the 
BBB permeability; the effect was sensitive to antagonism of PAF receptor. This finding is in 
agreement with a relatively recent study reporting a preserved integrity of blood-brain 
barrier in mice lacking the PAF receptor, PAFR(-/-) (Toscano et al, 2016). Blockade of Ca2+ 
influx or of NO formation also prevented the increase in BBB permeability produced by 
PAF, indicating a central role of the increase in [Ca2+]i and subsequent NO formation in this 
effect. Taken together, our studies identify multiple mechanisms by which PAF modulates 
the function of the brain microvascular endothelial cells and ultimately increases the 
permeability of the blood-brain barrier, relevant for the cerebrovascular inflammatory 
disorders.
Acknowledgments
This study was supported by startup funds from the Jefferson College of Pharmacy, and by the National Institutes of 
Health, National Institute on Drug Abuse [grants R01DA035926, R01NS086570 and P30DA013429].
References
Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-
brain barrier. Neurobiology of disease. 2010; 37:13–25. [PubMed: 19664713] 
Abbruscato TJ, Lopez SP, Mark KS, Hawkins BT, Davis TP. Nicotine and cotinine modulate cerebral 
microvascular permeability and protein expression of ZO-1 through nicotinic acetylcholine 
receptors expressed on brain endothelial cells. Journal of pharmaceutical sciences. 2002; 91:2525–
2538. [PubMed: 12434396] 
Aijaz S, Balda MS, Matter K. Tight junctions: molecular architecture and function. International 
review of cytology. 2006; 248:261–298. [PubMed: 16487793] 
Alexander SP, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, Pawson AJ, 
Sharman JL, Southan C, Davies JA, Collaborators C. The Concise Guide to PHARMACOLOGY 
2015/16: G protein-coupled receptors. British journal of pharmacology. 2015; 172:5744–5869. 
[PubMed: 26650439] 
Aliberti JC, Machado FS, Gazzinelli RT, Teixeira MM, Silva JS. Platelet-activating factor induces 
nitric oxide synthesis in Trypanosoma cruzi-infected macrophages and mediates resistance to 
parasite infection in mice. Infection and immunity. 1999; 67:2810–2814. [PubMed: 10338485] 
Altmann JB, Yan G, Meeks JF, Abood ME, Brailoiu E, Brailoiu GC. G protein-coupled estrogen 
receptor-mediated effects on cytosolic calcium and nanomechanics in brain microvascular 
endothelial cells. Journal of neurochemistry. 2015; 133:629–639. [PubMed: 25703621] 
Andras IE, Deli MA, Veszelka S, Hayashi K, Hennig B, Toborek M. The NMDA and AMPA/KA 
receptors are involved in glutamate-induced alterations of occludin expression and phosphorylation 
in brain endothelial cells. Journal of cerebral blood flow and metabolism : official journal of the 
International Society of Cerebral Blood Flow and Metabolism. 2007; 27:1431–1443.
Avdonin PV, Cheglakov IB, Tkachuk VA. Stimulation of non-selective cation channels providing Ca2+ 
influx into platelets by platelet-activating factor and other aggregation inducers. European journal of 
biochemistry. 1991; 198:267–273. [PubMed: 1710183] 
Brailoiu et al. Page 10
Neuroscience. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Barzaghi G, Sarau HM, Mong S. Platelet-activating factor-induced phosphoinositide metabolism in 
differentiated U-937 cells in culture. The Journal of pharmacology and experimental therapeutics. 
1989; 248:559–566. [PubMed: 2537401] 
Benveniste J, Henson PM, Cochrane CG. Leukocyte-dependent histamine release from rabbit platelets. 
The role of IgE, basophils, and a platelet-activating factor. The Journal of experimental medicine. 
1972; 136:1356–1377. [PubMed: 4118412] 
Bito H, Honda Z, Nakamura M, Shimizu T. Cloning, expression and tissue distribution of rat platelet-
activating-factor-receptor cDNA. European journal of biochemistry. 1994; 221:211–218. 
[PubMed: 8168510] 
Bito H, Nakamura M, Honda Z, Izumi T, Iwatsubo T, Seyama Y, Ogura A, Kudo Y, Shimizu T. 
Platelet-activating factor (PAF) receptor in rat brain: PAF mobilizes intracellular Ca2+ in 
hippocampal neurons. Neuron. 1992; 9:285–294. [PubMed: 1323312] 
Bkaily G, d'Orleans-Juste P, Naik R, Perodin J, Stankova J, Abdulnour E, Rola-Pleszczynski M. PAF 
activation of a voltage-gated R-type Ca2+ channel in human and canine aortic endothelial cells. 
British journal of pharmacology. 1993; 110:519–520. [PubMed: 8242226] 
Brailoiu E, Shipsky MM, Yan G, Abood ME, Brailoiu GC. Mechanisms of modulation of brain 
microvascular endothelial cells function by thrombin. Brain research. 2017; 1657:167–175. 
[PubMed: 27998795] 
Brailoiu GC, Deliu E, Console-Bram LM, Soboloff J, Abood ME, Unterwald EM, Brailoiu E. Cocaine 
inhibits store-operated Ca2+ entry in brainmicrovascular endothelial cells: critical role for sigma-1 
receptors. Biochem J. 2016; 473:1–5. [PubMed: 26467159] 
Brailoiu GC, Oprea TI, Zhao P, Abood ME, Brailoiu E. Intracellular Cannabinoid Type 1 (CB1) 
Receptors Are Activated by Anandamide. J Biol Chem. 2011; 286:29166–29174. [PubMed: 
21719698] 
Brauner T, Hulser DF, Strasser RJ. Comparative measurements of membrane potentials with 
microelectrodes and voltage-sensitive dyes. Biochimica et biophysica acta. 1984; 771:208–216. 
[PubMed: 6704395] 
Brown RC, Davis TP. Hypoxia/aglycemia alters expression of occludin and actin in brain endothelial 
cells. Biochemical and biophysical research communications. 2005; 327:1114–1123. [PubMed: 
15652512] 
Callea L, Arese M, Orlandini A, Bargnani C, Priori A, Bussolino F. Platelet activating factor is 
elevated in cerebral spinal fluid and plasma of patients with relapsing-remitting multiple sclerosis. 
Journal of neuroimmunology. 1999; 94:212–221. [PubMed: 10376955] 
Callies C, Fels J, Liashkovich I, Kliche K, Jeggle P, Kusche-Vihrog K, Oberleithner H. Membrane 
potential depolarization decreases the stiffness of vascular endothelial cells. Journal of cell science. 
2011; 124:1936–1942. [PubMed: 21558418] 
Coeffier E, Delautier D, Le Couedic JP, Chignard M, Denizot Y, Benveniste J. Cooperation between 
platelets and neutrophils for paf-acether (platelet-activating factor) formation. Journal of leukocyte 
biology. 1990; 47:234–243. [PubMed: 2307906] 
De Bock M, Wang N, Decrock E, Bol M, Gadicherla AK, Culot M, Cecchelli R, Bultynck G, Leybaert 
L. Endothelial calcium dynamics, connexin channels and blood-brain barrier function. Progress in 
neurobiology. 2013; 108:1–20. [PubMed: 23851106] 
Deng Y, Fang W, Li Y, Cen J, Fang F, Lv P, Gong S, Mao L. Blood-brain barrier breakdown by PAF 
and protection by XQ-1H due to antagonism of PAF effects. European journal of pharmacology. 
2009; 616:43–47. [PubMed: 19555682] 
Diserbo M, Cand F, Ziade M, Verdetti J. Stimulation of platelet-activating factor (PAF) receptors 
increases inositol phosphate production and cytosolic free Ca2+ concentrations in N1E-115 
neuroblastoma cells. Cell calcium. 1995; 17:442–452. [PubMed: 8521458] 
Fang W, Geng X, Deng Y, Li Y, Shang E, Cen J, Lv P. Platelet activating factor induces blood brain 
barrier permeability alteration in vitro. Journal of neuroimmunology. 2011; 230:42–47. [PubMed: 
20870297] 
Fang W, Zhang R, Sha L, Lv P, Shang E, Han D, Wei J, Geng X, Yang Q, Li Y. Platelet activating 
factor induces transient blood-brain barrier opening to facilitate edaravone penetration into the 
brain. Journal of neurochemistry. 2014; 128:662–671. [PubMed: 24164378] 
Brailoiu et al. Page 11
Neuroscience. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Feuerstein GZ. Platelet-activating factor: a case for its role in CNS function and brain injury. Journal of 
lipid mediators and cell signalling. 1996; 14:109–114. [PubMed: 8906553] 
Fleming I, Bauersachs J, Busse R. Calcium-dependent and calcium-independent activation of the 
endothelial NO synthase. Journal of vascular research. 1997; 34:165–174. [PubMed: 9226298] 
Gelbard HA, Nottet HS, Swindells S, Jett M, Dzenko KA, Genis P, White R, Wang L, Choi YB, Zhang 
D, et al. Platelet-activating factor: a candidate human immunodeficiency virus type 1-induced 
neurotoxin. Journal of virology. 1994; 68:4628–4635. [PubMed: 8207837] 
Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved 
fluorescence properties. J Biol Chem. 1985; 260:3440–3450. [PubMed: 3838314] 
Hallam TJ, Sanchez A, Rink TJ. Stimulus-response coupling in human platelets. Changes evoked by 
platelet-activating factor in cytoplasmic free calcium monitored with the fluorescent calcium 
indicator quin2. The Biochemical journal. 1984; 218:819–827. [PubMed: 6426464] 
Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. 
Pharmacological reviews. 2005; 57:173–185. [PubMed: 15914466] 
Hilliquin P, Houbaba H, Aissa J, Benveniste J, Menkes CJ. Correlations between PAF-acether and 
tumor necrosis factor in rheumatoid arthritis. Influence of parenteral corticosteroids. Scandinavian 
journal of rheumatology. 1995; 24:169–173. [PubMed: 7777830] 
Honda Z, Nakamura M, Miki I, Minami M, Watanabe T, Seyama Y, Okado H, Toh H, Ito K, Miyamoto 
T, et al. Cloning by functional expression of platelet-activating factor receptor from guinea-pig 
lung. Nature. 1991; 349:342–346. [PubMed: 1846231] 
Ihida K, Predescu D, Czekay RP, Palade GE. Platelet activating factor receptor (PAF-R) is found in a 
large endosomal compartment in human umbilical vein endothelial cells. Journal of cell science. 
1999; 112(Pt 3):285–295. [PubMed: 9885282] 
Jeewandara C, Gomes L, Wickramasinghe N, Gutowska-Owsiak D, Waithe D, Paranavitane SA, 
Shyamali NL, Ogg GS, Malavige GN. Platelet activating factor contributes to vascular leak in 
acute dengue infection. PLoS neglected tropical diseases. 2015; 9:e0003459. [PubMed: 25646838] 
Kamata K, Arai Y, Kasuya Y. Mechanism of the contractile response to platelet-activating factor (PAF) 
of the rat stomach fundus. I. PAF-induced contractile response and calcium mobilization. General 
pharmacology. 1993a; 24:1331–1336. [PubMed: 8112503] 
Kamata K, Arai Y, Kasuya Y. Mechanism of the contractile response to platelet-activating factor (PAF) 
of the rat stomach fundus. II. PAF-induced phosphatidylinositol turnover and desensitization. 
General pharmacology. 1993b; 24:1337–1341. [PubMed: 8112504] 
Kojima H, Nakatsubo N, Kikuchi K, Kawahara S, Kirino Y, Nagoshi H, Hirata Y, Nagano T. Detection 
and imaging of nitric oxide with novel fluorescent indicators: diaminofluoresceins. Anal Chem. 
1998; 70:2446–2453. [PubMed: 9666719] 
Kornecki E, Ehrlich YH. Neuroregulatory and neuropathological actions of the ether-phospholipid 
platelet-activating factor. Science. 1988; 240:1792–1794. [PubMed: 3381103] 
Kumar R, Harvey SA, Kester M, Hanahan DJ, Olson MS. Production and effects of platelet-activating 
factor in the rat brain. Biochimica et biophysica acta. 1988; 963:375–383. [PubMed: 3196741] 
Lacerda-Queiroz N, Rodrigues DH, Vilela MC, Rachid MA, Soriani FM, Sousa LP, Campos RD, 
Quesniaux VF, Teixeira MM, Teixeira AL. Platelet-activating factor receptor is essential for the 
development of experimental cerebral malaria. The American journal of pathology. 2012; 
180:246–255. [PubMed: 22079430] 
Leikert JF, Rathel TR, Muller C, Vollmar AM, Dirsch VM. Reliable in vitro measurement of nitric 
oxide released from endothelial cells using low concentrations of the fluorescent probe 4,5-
diaminofluorescein. FEBS letters. 2001; 506:131–134. [PubMed: 11591386] 
Lenzser G, Kis B, Snipes JA, Gaspar T, Sandor P, Komjati K, Szabo C, Busija DW. Contribution of 
poly(ADP-ribose) polymerase to postischemic blood-brain barrier damage in rats. Journal of 
cerebral blood flow and metabolism : official journal of the International Society of Cerebral 
Blood Flow and Metabolism. 2007; 27:1318–1326.
Lerner R, Lindstrom P, Palmblad J. Platelet activating factor and leukotriene B4 induce 
hyperpolarization of human endothelial cells but depolarization of neutrophils. Biochemical and 
biophysical research communications. 1988; 153:805–810. [PubMed: 2838025] 
Brailoiu et al. Page 12
Neuroscience. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Lin AY, Rui YC. Platelet-activating factor induced calcium mobilization and phosphoinositide 
metabolism in cultured bovine cerebral microvascular endothelial cells. Biochimica et biophysica 
acta. 1994; 1224:323–328. [PubMed: 7981248] 
Liu LB, Xue YX, Liu YH, Wang YB. Bradykinin increases blood-tumor barrier permeability by down-
regulating the expression levels of ZO-1, occludin, and claudin-5 and rearranging actin 
cytoskeleton. Journal of neuroscience research. 2008; 86:1153–1168. [PubMed: 18183615] 
Liu Y, Shields LB, Gao Z, Wang Y, Zhang YP, Chu T, Zhu Q, Shields CB, Cai J. Current 
Understanding of Platelet-Activating Factor Signaling in Central Nervous System Diseases. 
Molecular neurobiology. 2016
Maclennan KM, Smith PF, Darlington CL. Platelet-activating factor in the CNS. Progress in 
neurobiology. 1996; 50:585–596. [PubMed: 9015828] 
Mariano F, Bussolati B, Migliori M, Russo S, Triolo G, Camussi G. Platelet-activating factor synthesis 
by neutrophils, monocytes, and endothelial cells is modulated by nitric oxide production. Shock. 
2003; 19:339–344. [PubMed: 12688545] 
Molino Y, Jabes F, Lacassagne E, Gaudin N, Khrestchatisky M. Setting-up an in vitro model of rat 
blood-brain barrier (BBB): a focus on BBB impermeability and receptor-mediated transport. 
Journal of visualized experiments : JoVE. 2014:e51278. [PubMed: 24998179] 
Naccache PH, Molski MM, Volpi M, Shefcyk J, Molski TF, Loew L, Becker EL, Sha'afi RI. 
Biochemical events associated with the stimulation of rabbit neutrophils by platelet-activating 
factor. Journal of leukocyte biology. 1986; 40:533–548. [PubMed: 3021882] 
Predescu D, Ihida K, Predescu S, Palade GE. The vascular distribution of the platelet-activating factor 
receptor. European journal of cell biology. 1996; 69:86–98. [PubMed: 8825027] 
Predescu S, Knezevic I, Bardita C, Neamu RF, Brovcovych V, Predescu D. Platelet activating factor-
induced ceramide micro-domains drive endothelial NOS activation and contribute to barrier 
dysfunction. PloS one. 2013; 8:e75846. [PubMed: 24086643] 
Prescott SM, Zimmerman GA, Stafforini DM, McIntyre TM. Platelet-activating factor and related lipid 
mediators. Annual review of biochemistry. 2000; 69:419–445.
Radu M, Chernoff J. An in vivo assay to test blood vessel permeability. Journal of visualized 
experiments : JoVE. 2013:e50062. [PubMed: 23524912] 
Reiner B, Wang W, Liu J, Xiong H. Platelet-activating factor attenuation of long-term potentiation in 
rat hippocampal slices via protein tyrosine kinase signaling. Neuroscience letters. 2016; 615:83–
87. [PubMed: 26808643] 
Reinhold AK, Rittner HL. Barrier function in the peripheral and central nervous system-a review. 
Pflugers Archiv : European journal of physiology. 2017; 469:123–134. [PubMed: 27957611] 
Sanchez FA, Kim DD, Duran RG, Meininger CJ, Duran WN. Internalization of eNOS via caveolae 
regulates PAF-induced inflammatory hyperpermeability to macromolecules. American journal of 
physiology Heart and circulatory physiology. 2008; 295:H1642–1648. [PubMed: 18708444] 
Satoh K, Yoshida H, Imaizumi TA, Koyama M, Takamatsu S. Production of platelet-activating factor 
by porcine brain microvascular endothelial cells in culture. Thrombosis and haemostasis. 1995; 
74:1335–1339. [PubMed: 8607119] 
Shukla SD. Platelet-activating factor receptor and signal transduction mechanisms. FASEB journal : 
official publication of the Federation of American Societies for Experimental Biology. 1992; 
6:2296–2301. [PubMed: 1312046] 
Stoll LL, Denning GM, Kasner NA, Hunninghake GW. Platelet-activating factor may stimulate both 
receptor-dependent and receptor-independent increases in [Ca2+] in human airway epithelial cells. 
The Journal of biological chemistry. 1994; 269:4254–4259. [PubMed: 8307989] 
Stolwijk JA, Matrougui K, Renken CW, Trebak M. Impedance analysis of GPCR-mediated changes in 
endothelial barrier function: overview and fun damental considerations for stable and reproducible 
measurements. Pflugers Archiv : European journal of physiology. 2015; 467:2193–2218. 
[PubMed: 25537398] 
Stolwijk JA, Zhang X, Gueguinou M, Zhang W, Matrougui K, Renken C, Trebak M. Calcium 
Signaling Is Dispensable for Receptor Regulation of Endothelial Barrier Function. The Journal of 
biological chemistry. 2016; 291:22894–22912. [PubMed: 27624938] 
Brailoiu et al. Page 13
Neuroscience. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Tiemann U, Neels P, Kuchenmeister U, Walzel H, Spitschak M. Effect of ATP and platelet-activating 
factor on intracellular calcium concentrations of cultured oviductal cells from cows. Journal of 
reproduction and fertility. 1996; 108:1–9. [PubMed: 8958821] 
Tiemann U, Neels P, Pohland R, Walzel H, Lohrke B. Influence of inhibitors on increase in 
intracellular free calcium and proliferation induced by platelet-activating factor in bovine oviductal 
cells. Journal of reproduction and fertility. 1999; 116:63–72. [PubMed: 10505057] 
Toscano EC, Silva BC, Victoria EC, Cardoso AC, Miranda AS, Sugimoto MA, Sousa LP, Carvalho 
BA, Kangussu LM, Silva DG, Rodrigues FG, Barcelos Lda S, Vasconcelos AC, Amaral FA, 
Teixeira MM, Teixeira AL, Rachid MA. Platelet-activating factor receptor (PAFR) plays a crucial 
role in experimental global cerebral ischemia and reperfusion. Brain research bulletin. 2016; 
124:55–61. [PubMed: 27040712] 
Tsoupras AB, Iatrou C, Frangia C, Demopoulos CA. The implication of platelet activating factor in 
cancer growth and metastasis: potent beneficial role of PAF-inhibitors and antioxidants. Infectious 
disorders drug targets. 2009; 9:390–399. [PubMed: 19689381] 
Ukena D, Dent G, Birke FW, Robaut C, Sybrecht GW, Barnes PJ. Radioligand binding of antagonists 
of platelet-activating factor to intact human platelets. FEBS letters. 1988; 228:285–289. [PubMed: 
3342883] 
Uyama O, Okamura N, Yanase M, Narita M, Kawabata K, Sugita M. Quantitative evaluation of 
vascular permeability in the gerbil brain after transient ischemia using Evans blue fluorescence. 
Journal of cerebral blood flow and metabolism : official journal of the International Society of 
Cerebral Blood Flow and Metabolism. 1988; 8:282–284.
Vadas P, Perelman B, Liss G. Platelet-activating factor, histamine, and tryptase levels in human 
anaphylaxis. The Journal of allergy and clinical immunology. 2013; 131:144–149. [PubMed: 
23040367] 
Abbreviations
BBB blood-brain barrier
[Ca2+]i cytosolic Ca2+ concentration
ECIS Electric Cell-Substrate Impedance Sensing
HBSS Hanks' Balanced Salt Solution
NO nitric oxide
PBS phosphate buffer saline
RBMVEC rat brain microvascular endothelial cells
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Highlights
• We examined the effect of PAF on rat brain microvascular endothelial cells 
(RBMVEC) using in vitro and in vivo assays
• In addition to increasing cytosolic Ca2+ and NO production, we show for the 
first time that PAF depolarized RBMVEC
• PAF-induced changes in F-actin and tight junctions converged in a reduced 
electrical resistance and increased permeability
• Our results reveal multiple mechanisms by which PAF increases BBB 
permeability, relevant to CNS inflammatory disorders
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Figure 1. PAF increases cytosolic Ca2+ concentration, [Ca2+]i, by promoting Ca2+ influx in 
RBMVEC
A , Examples of fura-2 AM fluorescence ratio (F340/F380) in RBMVEC before (basal) and 
after treatment with PAF (1 μM). Cold colors represent low ratios and hot colors represent 
high ratio (scale 0-2). B, Representative examples (average ± SEM) of [Ca2+]i increases 
produced by PAF (1 μM) and PAF (1 μM) in the presence of PAF receptor antagonist 
WEB2086 (5 μM). PAF produced a fast and transient increase in [Ca2+]i; the response was 
inhibited by WEB2086. C, Comparison of the amplitude of [Ca2+]i increase produced by 
each concentration of PAF tested (0.1 μM, 0.5 μM, 1 μM and 5μM) and by PAF (1 μM) in 
cells pretreated with WEB2086 (5 μM). P < 0.05 as compared to the response to the other 
concentrations of PAF tested (*), or to the response produced by PAF 1 μM (#). D, In Ca2+-
free saline, PAF (1 μM) did not elicit an increase in [Ca2+]i., while ATP (50 μM) increased 
[Ca2+]i, indicating the integrity of internal Ca2+ stores. Pretreatment with the L-type Ca2+ 
channels blocker, nifedipine (1 μM), prevented the increase in [Ca2+]i produced by PAF. E, 
Comparison of the amplitude of [Ca2+]i responses elicited in Ca2+-free saline by PAF (1 
μM) and ATP (50 μM) (top) and in Ca2+-containing saline (bottom) by or PAF (1 μM) alone 
or by PAF (1 μM) in cells pretreated with nifedipine (1 μM) (bottom). P < 0.05 as compared 
to ATP-induced response in Ca2+-free (*) or to PAF-induced response in Ca2+-containing 
saline (#).
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Figure 2. PAF elicits RBMVEC depolarization
A, Averaged changes in membrane potential ± SEM in response to PAF (1 μM), PAF in the 
presence of the PAF antagonist, WEB2086 (5 μM), nifedipine (Nif, 1 μM) or L-NAME (100 
μM). Treatment of RBMVEC with PAF (1 μM) induced a depolarization that was prevented 
by WEB2086 (5 μM), and nifedipine (1 μM) but it was not affected by L-NAME. B, 
Comparison of the average amplitude of the depolarization produced by PAF alone or in the 
presence of WEB2086, nifedipine or L-NAME. *P < 0.05 as compared to the effect of PAF 
in presence of PAF antagonist, WEB2086, or nifedipine. NS, P > 0.05 between treatment 
groups.
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Figure 3. PAF increases NO production in RBMVEC
A , Averaged DAF-FM fluorescence ratios ± S.E.M. in cells treated with PAF (1 μM) (top 
left trace), PAF (1 μM) in the presence of WEB2086 (top right trace), PAF (1 μM) in the 
presence of L-NAME (bottom left trace) or PAF (1 μM) in the presence of nifedipine 
(bottom right trace). B, Comparison of ΔDAF-FM in cells treated with PAF (1 μM) in the 
absence and presence of WEB2086, L-NAME, or nifedipine (Nif). (*) P < 0.05 as compared 
to response to PAF alone. NS, P > 0.05 as compared to the other treatment groups.
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Figure 4. PAF produced cytoskeletal and tight junction changes and barrier dysfunction in 
RBMVEC
A, Distribution of ZO-1 (green), a component of tight junctions and F-actin (red), a 
component of cytoskeleton, in control RBMVEC, and cells treated with PAF (1 μM) in the 
absence and presence of PAF receptor antagonist. WEB2086. WEB2086, L-NAME and 
nifedipine (Nif) did not have any effect on ZO-1 or actin staining, but prevented the effect of 
PAF. Nuclei are stained with DAPI (blue). Treatment with PAF produced a reduction in 
ZO-1 staining, increased actin fibers, and intercellular gaps (arrows). B, Examples of 
changes in normalized electrical resistance of confluent RBMEC monolayer after histamine 
(10 μM), PAF (1 μM), PAF + WEB (5 μM). PAF, similarly to histamine, decreased electrical 
resistance; the response to PAF was abolished by WEB2086. C. PAF (0.1 μM – 5 μM) did 
not significantly affect RBMVEC viability assessed with MTT assay.
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Figure 5. PAF produced an increase in the permeability of the blood-brain barrier (BBB) in vivo
A, PAF (0.01 mg/kg) increased the permeability of the BBB assessed using the sodium 
fluorescein assay. B, PAF (0.01 mg/kg) increased the BBB permeability assessed using the 
Evans Blue method *P < 0.05 as compared to control, or to the effect of PAF in presence of 
PAF antagonist, WEB2086, L-NAME or nifedipine. NS, P > 0.05 between treatment groups.
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